What’s the real impact of the private equity overhang, just how big is it, and how worried should investors be? Expert analysis with professionals from ILPA, Cambridge and Independence Capital.

Michael Rogers, Global Deputy Sector Leader at EY, on what drove the momentum for private equity IPO exits in the first quarter of 2013.

Why are sellers selling in the revitalized U.S. manufacturing sector?

Alvaro Goncalves of Stratus Group explains how Brazil’s exchange for smaller listings, called the Bovespa Mais, is revolutionizing the capital markets and offering new exit opportunities to mid-market private equity firms.

Expert Q&A with Gustavo Gusmao, Executive Senior Manager, Lead Advisory – Public Sector at EY Terco.

Our expert panel explains how macroeconomic drivers and a demographic shift in consumer power are leading to fresh infrastructure investment opportunities in Brazil.

How do you know if an investment has the potential to overtake a market? Mike Duda of Consigliere Brand Capital explains.

Steve Menaker, Partner at McGladrey, on the role of the the firm’s transaction advisory group as a client engagement grows and evolves.

Pam Hendrickson of The Riverside Company explains the broad—and underappreciated—impact of the Affordable Care Act on middle-market private equity.

The senior executive from KKR shares the story of his experience with melanoma and describes the mission of the Melanoma Research Alliance.

In a candid joint interview, Debra and Leon Black tell the story of what led them to fund the creation of the Melanoma Research Alliance (MRA) with the guidance of their good friend, Michael Milken.

Having his youth under the sun as a sailor, Brendan Dillon was no stranger to sunburn. The senior executive at UBS shares the story of his diagnosis and why he is now involved with the Melanoma Research Alliance.